Mink Therapeutics IncNASDAQ:INKT
- LAST PRICE2.2400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.1600/ 1
- Ask / Lots2.3000/ 83
- Open / Previous Close0.0000 / 2.2400
- Day Range---
- 52 Week Range
- Volume5
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | INKT |
|---|
Jan 11, 2023
MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference, from 2:25PM ET on Wednesday Jan 11, 2023 by GlobeNewswire
2:25PM ET on Wednesday Jan 11, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mink Therapeutics Inc | 75.7M | -2.9x | --- |
Anebulo Pharmaceuticals Inc | 75.6M | -8.7x | --- |
Mustang Bio Inc | 75.5M | -0.9x | --- |
Viracta Therapeutics Inc | 74.9M | -1.5x | --- |
Spruce Biosciences Inc | 74.7M | -1.7x | --- |
Oncolytics Biotech Inc | 103.5M | -5.5x | --- |
Company Information
MiNK Therapeutics, Inc. is a biopharmaceutical company. The Company is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). The Company offers platform, which is designed for reproducible manufacturing for off-the-shelf delivery. Its product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is in multiple Phase I clinical trials, which is used for the treatment of multiple myeloma.
Contact Information
- Headquarters
- 149 Fifth Avenue, Suite 500NEW YORK, NY, United States 10010
- Phone
- 212-994-8250
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Garo Armen
- President, Chief Executive Officer, Director
- Jennifer Buell
- Chief Scientific Officer
- Marc Van Dijk
- Treasurer
- Christine Klaskin
- Independent Director
- John Baldoni
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $75.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.78 |
Book Value | $0.71 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
